GlobeImmune, Gilead in HBV deal

GlobeImmune Inc. (Louisville, Colo.) partnered with Gilead Sciences Inc. (NASDAQ:GILD) to develop and commercialize HBV vaccines for use in conjunction with oral suppressive antiviral therapies, including Gilead's Viread tenofovir. The deal will use GlobeImmune's Tarmogen products, which are whole, heat-killed, recombinant Saccharomyces cerevisiae genetically modified to express a disease-associated antigen. Gilead will provide support for GlobeImmune's development of GI-13000, a preclinical Tarmogen, through Phase Ia trials, after which Gilead will be responsible for development and commercialization. GlobeImmune will receive an upfront payment and is eligible for milestones and royalties. Details were not disclosed. ...